PLSE Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.79%, SMA50 -2.89%, SMA200 -13.25%). The stock’s 14-day RSI is 45.56 (neutral), while the ATR of 0.86 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -45.24% below its high and over 9.0% above its low. Average 10-day trading volume of 484.88 thousand shares is significantly above the 3-month average of 223.13 thousand, indicating heightened recent market interest.

Pulse Biosciences, Inc. generated EPS of -$1.14 over the past year. Five-year average earnings growth is 16.53%. Wall Street analysts project EPS growth of -10.66% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $22.00. The high target offers 6.02% upside. The low target suggests 6.02% downside. The mean target is $22.00. This offers 6.02% upside. Pulse Biosciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -7.2%. The prior quarter beat by 7.69%. Over the last six quarters, Apple has recorded several small beats. These include -12.5% in August 12, 2024.

Pulse Biosciences, Inc. has 67.28 million shares outstanding. The public float is 17.44 million shares, elevated short interest at 15.82% of float. This equals 2.45 million shares. The short ratio is 15.22 days. Institutional investors hold 34.65% of the float. Insiders own 73.93%. DUGGAN ROBERT W holds 47.55 million shares, UECKER DARRIN has 122.87 thousand shares and Zanganeh Maky has 86.67 thousand shares. Over the past six months, insider transactions show net selling. They sold 145.00 thousand shares across 8 transactions.

Pulse Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.87. This means the shares are trading above this model’s fair value.

Pulse Biosciences, Inc. (NASDAQ:PLSE) closed at $20.75 USD, gaining $7.06 (51.57%) from the previous close of $13.69. The stock is currently mid-range between its 52-week high and low $12.56 and $22.75. With a market capitalization of about $1.41 billion, Pulse Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 184.37 thousand shares, trading with heavier-than-usual volume. Headquartered in Miami, CA, Pulse Biosciences, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Paul Arthur LaViolette, the company employs approximately 75 people and listed since May 18, 2016. Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.

Pulse Biosciences, Inc. trades at a P/E ratio of -17.79, slightly below the S&P 500 average, with a price-to-sales ratio of 15551.08 and a price-to-book ratio of 14.35 reflecting a rich premium to book value. The P/FCF stands at -27.42, also below market averages. Compared to sector medians, Pulse Biosciences, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Pulse Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -31.81%, with price expected at $14.15 by February 19, 2026, within a range of $13.55 to $14.77 3-Month Outlook: Projected fall of -62.65%, reaching $7.75 by May 06, 2026, with a range of $7.23 to $8.18. 1-Year Outlook: Projected loss of -14.02%, with price at $17.84 by February 05, 2027, within a range of $4.25 to $26.49.

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares are flat 0.73% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pulse Biosciences, Inc. trading at a premium to the broader market with a P/E of -17.79. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $25.57, suggesting 23.23% upside. Our AI forecast model points to short-term weakness (-31.81% over two weeks), a medium-term fall (-62.65% over three months), and a longer-term loss (-14.02% over one year), with expected trading ranges indicating moderate volatility.